Dexfenfluramine

ALIMENTARY TRACT AND METABOLISM

Key facts

Dexfenfluramine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1970. DrugCentral lists 21 molecular targets, including ADRA1B, ADRA2C and SIGMAR1. Recorded indications include Obesity.

• Molecular targets: ADRA1B, ADRA2C, SIGMAR1 and ADRA2B (21 listed in DrugCentral).
• Indications: Obesity.
• ATC code: A08AA04 (Centrally acting antiobesity products).
• Molecular formula: C12H16F3N; molecular weight 231.26 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Obesity

Contraindications (6)

• Alcoholism
• Diabetes mellitus type 1
• Diabetes mellitus type 2
• Glaucoma
• Hypertensive disorder
• Pulmonary hypertension

Mechanism & targets

Molecular targets (21)

Target	Gene	Action	Activity
Alpha-1B adrenergic receptor	ADRA1B	unknown	Ki 6.85
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.71
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 6.66
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.62
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 6.57
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.28
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 6.18
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 6.08
Beta-1 adrenergic receptor	ADRB1	unknown	Ki 6.00
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 5.90
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 5.79
Muscarinic acetylcholine receptor M1	CHRM1	unknown	Ki 5.73
5-hydroxytryptamine receptor 1B	HTR1B	unknown	Ki 5.72
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 5.61
Muscarinic acetylcholine receptor M2	CHRM2	unknown	Ki 5.58
5-hydroxytryptamine receptor 1A	Htr1a	unknown	IC50 5.47
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 5.38
Muscarinic acetylcholine receptor M3	CHRM3	unknown	Ki 5.33
5-hydroxytryptamine receptor 7	HTR7	unknown	Ki 5.26
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 5.16

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1970-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
A08AA04	ALIMENTARY TRACT AND METABOLISM › ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS › ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS › Centrally acting antiobesity products

Chemical structure

• Molecular formula: C₁₂H₁₆F₃N
• Molecular weight: 231.26 g/mol
• CAS number: 3239-44-9
• InChIKey: DBGIVFWFUFKIQN-VIFPVBQESA-N
• PubChem CID: 66265

CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dexfenfluramine used for?

DrugCentral lists the following indications for Dexfenfluramine: Obesity.

How does Dexfenfluramine work?

Its molecular targets in DrugCentral include ADRA1B, ADRA2C, SIGMAR1 and ADRA2B.

When was Dexfenfluramine first approved?

Dexfenfluramine was first approved by the YEAR INTRODUCED in 1970.

What is the chemical formula of Dexfenfluramine?

Dexfenfluramine has the molecular formula C12H16F3N and a molecular weight of 231.26 g/mol.

Sources

• DrugCentral drug card 832 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1887891 — compound record and bioactivity
• PubChem CID 66265 — chemical identifiers
• DrugBank DB00574 — drug record
• FDA UNII E35R3G56OV — substance identity
• UniProt P35368 (ADRA1B) — target protein
• UniProt P18825 (ADRA2C) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• UniProt P18089 (ADRA2B) — target protein
• UniProt P35348 (ADRA1A) — target protein
• UniProt P08913 (ADRA2A) — target protein

How this page is built: methodology · editorial policy & corrections.